LIAN - Medical Device Maker Highlights China Risk As Chinese U.S. IPOs Resume
- Meihua International files updated prospectus highlighting China oversight risk in latest filing for its modest $57 million U.S. IPO.
- Hotel operator Atour makes similar updated filing for U.S. IPO plan to raise $350 million, valuing the company at more than $2 billion.
- LianBio's shares fizzle in its trading debut, falling 14% on its first trading day, as it became the first major New York listing by a Chinese company since a halt in July.
For further details see:
Medical Device Maker Highlights China Risk As Chinese U.S. IPOs Resume